Dr Matteo Serenelli
- Affiliate (School of Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)
Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)